A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19

Suresh Kumar; Rosemarie De Souza; Milind Nadkar; Randeep Guleria; Anjan Trikha; Shashank R. Joshi; Subramanian Loganathan; Sivakumar Vaidyanathan; Ashwani Marwah; Sandeep N. Athalye

Expert Opinion on Biological Therapy (2021) - Comments
pubmed: 33835886 doi: 10.1080/14712598.2021.1905794 issn: 1471-2598 issn: 1744-7682

Suresh Kumar, Rosemarie De Souza, Milind Nadkar, Randeep Guleria, Anjan Trikha, Shashank R. Joshi, Subramanian Loganathan, Sivakumar Vaidyanathan, Ashwani Marwah, Sandeep N. Athalye